title: Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.
abstract: HLA-A,B,C and HLA-D molecules present antigenic peptides to the antigen-specific receptor of autologous T-lymphocytes. T-cell-mediated host-versus-tumor response might therefore depend on the presence of these molecules on tumor cells, although the absence of HLA-A,B,C determinants on a cell has been shown to increase its susceptibility to lysis by natural killer cells. To investigate whether the presence or absence of HLA-A,B,C and/or HLA-DR in colorectal carcinoma influences relapse rate and time of tumor-related death, 152 patients who underwent putatively curative surgical treatment were surveyed for a maximum of 65 months (mean, 48 months). As determined by immunohistochemistry, aberrant reduction or loss of HLA-A,B,C/beta 2-microglobulin molecules was more frequent in tumors of the proximal colon than of the rectosigmoid (P = 0.032) and in mucinous carcinomas than in nonmucinous ones (P = 0.022). An abnormal induction of the HLA-D-associated invariant chain (Ii) was more frequent in Dukes' A and B than in stage C (P = 0.046). Reduction/loss of HLA-A,B,C/beta 2-microglobulin was correlated with the absence of HLA-DR (P = 0.024) and Ii (P = 0.005). In contrast to the prognostic role of tumor stage and grade, the presence versus the absence of HLA-A,B,C/beta 2-microglobulin and HLA-DR/Ii molecules was not correlated with recurrence rate or survival. We conclude that in spite of an increasing amount of experimental data suggesting the contrary, the status of HLA-A,B,C and HLA-DR expression in colorectal carcinoma seems to be irrelevant in vivo, regarding survival and growth of residual tumor cells after putatively curative resection of the initial tumor burden.
authors.affiliation: Institute of Pathology, Heidelberg University, Federal Republic of Germany.
authors.forename: P
authors.initials: P
authors.lastname: Möller
authors.forename: F
authors.initials: F
authors.lastname: Momburg
authors.forename: K
authors.initials: K
authors.lastname: Koretz
authors.forename: G
authors.initials: G
authors.lastname: Moldenhauer
authors.forename: C
authors.initials: C
authors.lastname: Herfarth
authors.forename: H F
authors.initials: HF
authors.lastname: Otto
authors.forename: G J
authors.initials: GJ
authors.lastname: Hämmerling
authors.forename: P
authors.initials: P
authors.lastname: Schlag
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000601:surgery; D015179:Colorectal Neoplasms / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D015234:HLA-A Antigens / Q000032:analysis; D015235:HLA-B Antigens / Q000032:analysis; D015236:HLA-C Antigens / Q000032:analysis; D006681:HLA-D Antigens / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis*; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II